JP2019500944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500944A5 JP2019500944A5 JP2018530136A JP2018530136A JP2019500944A5 JP 2019500944 A5 JP2019500944 A5 JP 2019500944A5 JP 2018530136 A JP2018530136 A JP 2018530136A JP 2018530136 A JP2018530136 A JP 2018530136A JP 2019500944 A5 JP2019500944 A5 JP 2019500944A5
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- sponge
- article
- chitosan
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims description 43
- 229920001282 polysaccharide Polymers 0.000 claims description 43
- 239000005017 polysaccharide Substances 0.000 claims description 43
- 229920001661 Chitosan Polymers 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 14
- 238000012669 compression test Methods 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 8
- 238000007922 dissolution test Methods 0.000 claims description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 3
- 239000005714 Chitosan hydrochloride Substances 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 230000003232 mucoadhesive effect Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920000926 Galactomannan Polymers 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- -1 Zorbax Diol Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/962,493 US20170157283A1 (en) | 2015-12-08 | 2015-12-08 | Dissolvable nasal sinus sponge |
| US14/962,493 | 2015-12-08 | ||
| PCT/US2016/064234 WO2017100057A1 (en) | 2015-12-08 | 2016-11-30 | Dissolvable nasal sinus sponge |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500944A JP2019500944A (ja) | 2019-01-17 |
| JP2019500944A5 true JP2019500944A5 (enrdf_load_stackoverflow) | 2020-01-23 |
| JP6962919B2 JP6962919B2 (ja) | 2021-11-05 |
Family
ID=57570593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530136A Active JP6962919B2 (ja) | 2015-12-08 | 2016-11-30 | 溶解可能な鼻洞スポンジ |
Country Status (8)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170157283A1 (en) | 2015-12-08 | 2017-06-08 | Medtronic Xomed, Inc. | Dissolvable nasal sinus sponge |
| US10576099B2 (en) | 2016-10-21 | 2020-03-03 | Covidien Lp | Injectable scaffold for treatment of intracranial aneurysms and related technology |
| USD813481S1 (en) * | 2017-02-22 | 2018-03-20 | Turtle Wax, Inc. | Sponge |
| WO2019123389A1 (en) | 2017-12-20 | 2019-06-27 | Stryker European Holdings I, Llc | Biomedical foam |
| CN109224114B (zh) * | 2018-10-10 | 2021-06-04 | 广州润虹医药科技股份有限公司 | 一种泡沫敷料及其制备方法和应用 |
| CN109893678B (zh) * | 2019-02-28 | 2021-09-03 | 武汉大学 | 一种累托石-甲壳素纳米凝胶复合止血材料及其制备方法 |
| US11826863B2 (en) | 2019-11-04 | 2023-11-28 | Covidien Lp | Systems and methods for treating aneurysms |
| US12364793B2 (en) | 2021-03-16 | 2025-07-22 | Covidien Lp | Injectable biopolymer compositions and associated systems and methods |
| CN112999407B (zh) * | 2021-03-25 | 2022-07-12 | 杭州维力医疗器械有限公司 | 一种可降解止血海绵及其制备方法和其应用、一种可降解载药止血海绵 |
| CN113599565B (zh) * | 2021-09-29 | 2021-12-31 | 诺一迈尔(山东)医学科技有限公司 | 梯度降解的医用海绵及其制备方法 |
| CN115054722A (zh) * | 2022-07-07 | 2022-09-16 | 宁波旸曜医疗科技有限公司 | 一种止血海绵的制备方法、止血海绵 |
| CN116637228B (zh) * | 2023-02-07 | 2025-04-22 | 江西博恩锐尔生物科技有限公司 | 一种可凝胶化纤维素复合海绵及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| ATA13842001A (de) | 2001-08-31 | 2002-10-15 | Mucobiomer Biotechnologische F | Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung |
| JP2003159528A (ja) * | 2001-11-27 | 2003-06-03 | Unitika Ltd | 吸水材及びそれを含む吸水性物品 |
| EP1912659A4 (en) | 2005-08-05 | 2012-09-19 | Hemostasis Llc | ANTIMICROBIAL COMPOSITION AND CORRESPONDING SYSTEM |
| US20070104769A1 (en) * | 2005-11-04 | 2007-05-10 | Lifescience Plus, Inc. | Bioabsorbable hemostatic gauze |
| BRPI0708429A2 (pt) * | 2006-03-01 | 2011-05-31 | Fmc Biopolymer As | método para formar uma espuma absorvente seca, espuma absorvente seca, compósito, uso de uma espuma ou de um compósito, e, métodos para inibir a proliferação celular, para fixar um compósito ao tecido e para evitar a adesão de tecido a tecido adjacente |
| US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
| US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US8313762B2 (en) | 2006-07-05 | 2012-11-20 | Medtronic Xomed, Inc. | Flexible bioresorbable hemostatic packing and stent |
| US8623842B2 (en) | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
| JP2010511427A (ja) | 2006-12-01 | 2010-04-15 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | コラーゲン阻害剤を含む医療デバイス |
| EP2167144A4 (en) * | 2007-06-13 | 2012-11-21 | Fmc Corp | DEGRADABLE, IMPLANTABLE DEVICES BASED ON BIOPOLYMERS |
| US9061087B2 (en) | 2008-03-04 | 2015-06-23 | Hemostasis, Llc | Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor |
| EP2296637B1 (en) | 2008-04-24 | 2014-04-02 | Medtronic, Inc | Chitosan-containing protective composition |
| CA2722155C (en) * | 2008-04-24 | 2019-07-30 | Medtronic, Inc. | Cold ionizing radiation sterilization |
| US9205049B2 (en) | 2008-06-19 | 2015-12-08 | University Of The Witwatersrand, Johannesburg | Transmucosal delivery system |
| US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| US20110052663A1 (en) | 2009-09-01 | 2011-03-03 | Hemostasis, Llc | Hemostatic Sponge with Enzyme and Method of Manufacture |
| US20160184564A1 (en) | 2014-12-31 | 2016-06-30 | Michael R. Spearman | Intranasal delivery device and method of material delivery |
| US20170157283A1 (en) * | 2015-12-08 | 2017-06-08 | Medtronic Xomed, Inc. | Dissolvable nasal sinus sponge |
-
2015
- 2015-12-08 US US14/962,493 patent/US20170157283A1/en not_active Abandoned
-
2016
- 2016-11-30 WO PCT/US2016/064234 patent/WO2017100057A1/en not_active Ceased
- 2016-11-30 JP JP2018530136A patent/JP6962919B2/ja active Active
- 2016-11-30 KR KR1020187018894A patent/KR20180091864A/ko not_active Withdrawn
- 2016-11-30 CA CA3006565A patent/CA3006565A1/en not_active Abandoned
- 2016-11-30 EP EP16813266.0A patent/EP3386456B1/en active Active
- 2016-11-30 CN CN201680071757.7A patent/CN108366883B/zh active Active
- 2016-11-30 AU AU2016368748A patent/AU2016368748B2/en active Active
-
2018
- 2018-04-16 US US15/954,471 patent/US10517986B2/en active Active
-
2019
- 2019-12-06 US US16/706,209 patent/US11045577B2/en active Active
-
2021
- 2021-06-28 US US17/360,691 patent/US11839693B2/en active Active
-
2023
- 2023-11-17 US US18/513,436 patent/US12419989B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500944A5 (enrdf_load_stackoverflow) | ||
| Mali et al. | Citric Acid Crosslinked Carboxymethyl Cellulose-based Composite Hydrogel Films for Drug Delivery. | |
| US12419989B2 (en) | Solid solution compositions comprising cannabidiols | |
| US11229724B2 (en) | Biocompatible and bioabsorbable derivatized chitosan compositions | |
| JP5738753B2 (ja) | 再水和可能な多糖粒子およびスポンジ | |
| Kumar et al. | Recent advances in the use of algal polysaccharides for skin wound healing | |
| Kondaveeti et al. | Sustainable hydroxypropyl methylcellulose/xyloglucan/gentamicin films with antimicrobial properties | |
| JP2011522879A5 (enrdf_load_stackoverflow) | ||
| US20070077271A1 (en) | Medical devices coated with a fast dissolving biocompatible coating | |
| Erden et al. | Preparation and in vitro characterization of laminarin based hydrogels | |
| US10414833B2 (en) | Biocompatible composition and method for preparing same | |
| Lopez-Montero et al. | Sertaconazole-loaded cyclodextrin–polysaccharide hydrogels as antifungal devices | |
| EP3307789A1 (en) | Useful polysaccharide after radiation sterilization | |
| JP3046110B2 (ja) | 繊維−キトサン複合多孔質体、それを用いた吸収性パッド及び薬液含浸パッド | |
| Cardoso | Enzymatic degradation of natural polysaccharide-based layer-by-layer devices |